Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones
Piramal Pharma Limited released its FY2026 Annual Report, reporting revenue of ₹8,869 crore despite global economic disruptions. The company emphasized its focus on science-led innovation and a resilient global manufacturing footprint.
Why it matters
As a major pharmaceutical player, Piramal's financial performance and strategic outlook provide insight into the health of the global contract manufacturing sector.
MUMBAI, India , July 7, 2026 /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects Piramal Pharma's continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.
The article summarizes corporate financial disclosures without editorializing or taking a stance on the company's performance.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in